Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

The effects of extrafine beclomethasone/formoterol on hyperinflation and airway geometry in COPD patients

Samir Vinchurkar, Wim Vos, Cedric Holsbeke, Jan De Backer, Gianluigi Poli, Wilfried De Backer
European Respiratory Journal 2012 40: P4833; DOI:
Samir Vinchurkar
1Research and Development, FluidDA nv, Kontich, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim Vos
1Research and Development, FluidDA nv, Kontich, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cedric Holsbeke
1Research and Development, FluidDA nv, Kontich, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan De Backer
1Research and Development, FluidDA nv, Kontich, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianluigi Poli
2Research and Development, CHIESI, Parma, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilfried De Backer
3Respiratory Medicine, University Hospital Antwerp, Edegem, Antwerpen, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim of this study was to assess the effects of extrafine beclomethasone⁄formoterol treatment on lung hyperinflation and airway geometry in COPD. Data of lobar volume (%pred) and specific lobar airway volumes (siVaw) at FRC and TLC were obtained with functional imaging in 25 COPD patients (GOLD II 14, III 7, IV 4) pre- and 4h post-bronchodilator (post BD) both at baseline and after 6 months of treatment. A post BD drop was observed for both functional residual capacity (FRC) and total lung capacity (TLC) lobar volumes at baseline (FRC:-10%,p<0.01;TLC:-2%,p<0.01) and after 6 months (FRC:-12%,p<0.01;TLC:-2%,p<0.01) as index of reduced hyperinflation. siVaw did increase 4 hours after administration at both time points (+10%,p<0.01, and +8%,p<0.01).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

The 4h post-BD drop in hyperinflation at FRC was positively associated with the degree of hyperinflation (r=0.4, p<0.01). A drop in pre-bronchodilation hyperinflation was also observed at TLC after 6 months of treatment (-1%, p<0.01). Extrafine beclomethasone/formoterol decreased hyperinflation and increased airway volume in COPD patients 4h after bronchodilator. Moreover the chronic treatment over 6 months decreased also the pre-bronchodilator hyperinflation at TLC, indicating a progressive reduction of air trapping with treatment.

  • Airway management
  • COPD - management
  • COPD - mechanism
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effects of extrafine beclomethasone/formoterol on hyperinflation and airway geometry in COPD patients
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The effects of extrafine beclomethasone/formoterol on hyperinflation and airway geometry in COPD patients
Samir Vinchurkar, Wim Vos, Cedric Holsbeke, Jan De Backer, Gianluigi Poli, Wilfried De Backer
European Respiratory Journal Sep 2012, 40 (Suppl 56) P4833;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The effects of extrafine beclomethasone/formoterol on hyperinflation and airway geometry in COPD patients
Samir Vinchurkar, Wim Vos, Cedric Holsbeke, Jan De Backer, Gianluigi Poli, Wilfried De Backer
European Respiratory Journal Sep 2012, 40 (Suppl 56) P4833;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice
  • Modulation of inflammation by benralizumab in eosinophilic airway disease
  • WNT-4 regulates pro-inflammatory responses driven by epithelial-mesenchymal cross-talk
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society